61. 自己免疫性溶血性貧血 [臨床試験数:90,薬物数:72(DrugBank:23),標的遺伝子数:19,標的パスウェイ数:147

Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-004835-30-FI
(EUCTR)
10/07/201317/06/2013Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy.Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy. - CAD5 Primary chronic cold agglutinin disease requiringtreatment;Therapeutic area: Diseases [C] - Cancer [C04]Trade Name: Levact
INN or Proposed INN: BENDAMUSTINE HYDROCHLORIDE
Trade Name: MabThera
INN or Proposed INN: RITUXIMAB
Department of Medicine, Haugesund HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Finland;Norway
2EUCTR2011-004835-30-DK
(EUCTR)
17/01/201330/11/2012Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy.Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy. - CAD5 Primary chronic cold agglutinin disease requiringtreatment;Therapeutic area: Diseases [C] - Cancer [C04]Trade Name: Levact
INN or Proposed INN: BENDAMUSTINE HYDROCHLORIDE
Trade Name: MabThera
INN or Proposed INN: RITUXIMAB
Department of Medicine, Haugesund HospitalNULLNot RecruitingFemale: yes
Male: yes
50Phase 2Finland;Denmark;Norway
3NCT02689986
(ClinicalTrials.gov)
January 201316/2/2016Bendamustine and Rituximab Combination Therapy for Cold Agglutinin DiseaseThe CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination TherapyCold Agglutinin Disease;Autoimmune Hemolytic AnemiaDrug: Bendamustine, RituximabHelse FonnaNULLCompleted18 YearsN/AAll43Phase 2Denmark;Finland;Norway
4EUCTR2011-004835-30-NO
(EUCTR)
23/10/201229/08/2012Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy.Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy. - CAD5 Primary chronic cold agglutinin disease requiringtreatment;Therapeutic area: Diseases [C] - Cancer [C04]Trade Name: Levact
INN or Proposed INN: BENDAMUSTINE HYDROCHLORIDE
Trade Name: MabThera
INN or Proposed INN: RITUXIMAB
Department of Medicine, Haugesund HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Norway
5NCT01181154
(ClinicalTrials.gov)
March 3, 201112/8/2010Rituximab in Auto-Immune Hemolytic AnemiaRituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled TrialWarm Autoimmune Hemolytic AnemiaDrug: rituximab (Mabthera®);Drug: PlaceboAssistance Publique - Hôpitaux de ParisHoffmann-La RocheCompleted18 YearsN/AAll32Phase 3France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00960713
(ClinicalTrials.gov)
June 200916/7/2009The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune DisordersThe RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune DisordersPemphigus;Auto-immune Thrombocytopenic Purpura;Hemolytic Auto-immune Anaemia;Cold Agglutinin Disease;CryoglobulinemiaDrug: Rituximab (MABTHERA® or RITUXAN®).University Hospital, ToulouseNULLCompleted18 YearsN/ABoth35N/AFrance
7NCT01345708
(ClinicalTrials.gov)
January 200928/4/2011A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic AnemiaA Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Disease (Cold Type) (Warm Type)Drug: prednisone, low dose rituximabFondazione OspedaleUniversity Hospital, Udine, ItalyCompleted18 YearsN/ABoth23Phase 2Italy
8EUCTR2008-006713-25-IT
(EUCTR)
23/09/200816/01/2009A SINGLE-ARM PILOT STUDY WITH LOW-DOSE RITUXIMAB PLUS STANDARD ORAL PREDNISONE IN IDIOPATHIC AUTOIMMUNE HEMOLYTIC ANEMIA - NDA SINGLE-ARM PILOT STUDY WITH LOW-DOSE RITUXIMAB PLUS STANDARD ORAL PREDNISONE IN IDIOPATHIC AUTOIMMUNE HEMOLYTIC ANEMIA - ND ANEMIE EMOLITICHE AUTOIMMUNI IDIOPATICHEINN or Proposed INN: RituximabOSPEDALE MAGGIORE DI MILANO (IRCCS)NULLNot RecruitingFemale: yes
Male: yes
Italy
9NCT00373594
(ClinicalTrials.gov)
June 20057/9/2006Therapy for Chronic Cold Agglutinin DiseaseTherapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine.Cold Agglutinin DiseaseDrug: Rituximab;Drug: FludarabineUniversity of BergenNULLCompleted18 Years90 YearsBoth30Phase 2Norway;Russian Federation
10NCT01134432
(ClinicalTrials.gov)
March 200528/5/2010Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic AnemiaAnti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial.Anemia, Hemolytic, AutoimmuneDrug: prednisolone + mabthera;Drug: PrednisoloneCopenhagen University Hospital at HerlevNULLCompleted18 YearsN/ABoth65Phase 3Denmark